Autopsy report · NCT05077969

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

“Low recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 6 months before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 2 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Leidos Life Sciences

Sponsor type

Industry

Conditions

2019 Novel Coronavirus Disease; 2019 Novel Coronavirus Infection; 2019-nCoV Disease; 2019-nCoV Infection; COVID-19; COVID-19 Pandemic

Interventions

Famotidine; Celecoxib; Placebo

Participants

4

Sites

15

Countries

United States

Trials that died the same way

• Impact of Methadone on Prolonged Mechanical Ventilation in Patients on Continuous Treatment With Opioids
  “very low recruitment” (95% match in meaning)
• Study of Psychomotor Development and Attachment in Children Aged 6 to 30 Months With Oral Disorder
  “Recruitment too low” (92% match in meaning)
• A CFit Study - Baseline
  “Poor recruitment” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.